Impact of
biopharmaceutics classification system-based biowaivers.
Benita, "Self-dispersing lipid formulations for improving oral absorption of lipophilic drugs," European Journal of Pharmaceutics and
Biopharmaceutics, vol.
Predicting drug disposition via application of BCS: trans-port/absorption/elimination interplay and development of a
biopharmaceutics drug disposition classification system.
Biopharmaceutics & Drug Disposition, 10: 43-53.
Journal of
Biopharmaceutics & Biotechnology" is targeted to professionals in pharmaceutical sciences, medicine, medicinal chemistry, biotechnology, bioinformatics, biochemical engineering and the biomedical sciences.
Bernard Cabana, ActivBiotics' VP of Preclinical and Clinical Pharmacology and former founder and Director of the FDA's Division of
Biopharmaceutics, stated, "The pharmacokinetic and tissue distribution of rifalazil is best described by a two-compartment open-model.
Sectors covered include human and animal healthcare (biomedical developments, functional genomics and gene analyses, proteomics, diagnosis and diagnostics, molecular cellular monitoring, medical microbiology),
biopharmaceutics (novel therapeutics, vaccines, gene therapy), foods and beverages (novel foods, nutriceuticals, functional foods), agriculture and horticulture (plant and animal breeding, plant resistance and tolerance, biopesticides, bio-insecticides), and environmental protection and control (bioremediation and biodegradation, biomonitoring and control, air pollution treatment, ecological risks, hazards assessment).
The
Biopharmaceutics Section, headed by Iain McGilveray, FCIC, is involved in a number of clinical projects based on bioanalytical chemistry; specifically development and application of methods for measurement of drugs and their metabolites in tissue, mainly in blood plasma.
and for the FDA office of Clinical Pharmacology and
Biopharmaceutics as a reviewer of more than 50 NDA and sNDA submissions and more than 200 IND submissions.
Spiro Spireas, the inventor and author of more than 80 international and domestic patents and 200 scientific papers, books and other publications in the fields of industrial pharmacy,
biopharmaceutics, pharmacokinetics, pharmaceutical technology and analytical chemistry, founded Sigmapharm in 2005 and is the company's chairman and chief executive officer.
American Association of Pharmaceutical Scientists (AAPS) members primarily come from a pharmaceutics,
biopharmaceutics, or pharmacy field of study.
His industry experience includes but is not limited to previous positions as president of GloboMax Americas and director of
Biopharmaceutics and Pharmacokinetics at Schering-Plough Research, Miami.
